Pharmarise Holdings Corporation
Simbols: 2796.T
JPX
659
JPYTirgus cena šodien
24.8104
P/E koeficients
-0.9523
PEG koeficients
7.41B
MRK Cap
- 0.02%
DIV ienesīgums
Pharmarise Holdings Corporation (2796-T) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4742 | 3991 | 4604 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | -1926 | -2079 | -2427 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 605 | 479 | 926 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 2290 | 2302 | 2587 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 317 | 315 | 260 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 11372 | 10878 | 10546 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 6007 | 6355 | 6432 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2748 | 3220 | 4025 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 501 | 408 | 438 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3249 | 3628 | 4463 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 2008 | 2139 | 2488 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 778 | 741 | 786 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 4 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 12042 | 12863 | 14173 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 7 | 5 | 5 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 4252 | 4109 | 4609 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3677 | 2490 | 2819 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 333 | 429 | 573 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5461 | 7422 | 7878 | ||||||||||||||||
Deferred Revenue Non Current | 0 | -42 | -31 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 747 | 691 | 645 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 6600 | 8571 | 9001 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 432 | 551 | 700 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 16435 | 17048 | 18393 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 1298 | 1274 | 1251 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4014 | 3811 | 3494 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 226 | 203 | 208 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1343 | 1319 | 1268 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6881 | 6607 | 6221 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 105 | 91 | 110 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 6986 | 6698 | 6331 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 82 | 60 | 61 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 9138 | 9912 | 10697 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | 4396 | 5921 | 6093 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 513 | -1465 | -139 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 482 | -1319 | 365 | ||||||||||||||||
cash-flows.row.inventory | 0 | 68 | 286 | 56 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 13 | -500 | -582 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -50 | 68 | 22 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -266 | -452 | -462 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -180 | 2 | -116 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -2 | -2 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 383 | 12 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 19 | -209 | -418 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -703 | -292 | -1076 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2419 | -2636 | -2857 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 1737 | 2199 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -36 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -131 | -131 | -129 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1478 | -2 | 95 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -1072 | -1034 | -728 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2 | 0 | -1 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 743 | -613 | 140 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 4734 | 3991 | 4604 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3991 | 4604 | 4464 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 2520 | 713 | 1945 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 1978 | 247 | 1393 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 52030 | 51608 | 52324 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 43896 | 43491 | 44256 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 8134 | 8117 | 8068 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 6695 | 6596 | 6821 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 50591 | 50087 | 51077 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 1 | 1 | 1 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 1438 | 1520 | 1246 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 702 | 863 | 782 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 333 | 447 | 426 |
Biežāk uzdotie jautājumi
Kas ir Pharmarise Holdings Corporation (2796.T) kopējie aktīvi?
Pharmarise Holdings Corporation (2796.T) kopējie aktīvi ir 23421000000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.156.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 152.963.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.006.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.026.
Kāda ir Pharmarise Holdings Corporation (2796.T) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 333000000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 9138000000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 6695000000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.